Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway

(2011) Ralf A. Linker et al.   BRAIN

Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial

(2011) Douglas S Goodin et al.   Multiple Sclerosis Journal

Interferon  -1b and glatiramer acetate effects on permanent black hole evolution

(2011) M. Filippi et al.   NEUROLOGY

Efficacy of Fumaric Acid Esters in the R6/2 and YAC128 Models of Huntington's Disease

(2011) Gisa Ellrichmann et al.   PLoS One

The Nrf2-ARE Pathway

(2010) Jeffrey A. Johnson et al.   Annals of the New York Academy of Sciences

Innovations driving biomarker evaluation and use

(2010) John A Wagner   Biomarkers in Medicine

The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability

(2010) Antonio Scalfari et al.   BRAIN

Glatiramer Acetate

(2010) Natalie J. Carter et al.   DRUGS

IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci

(2010)   GENES AND IMMUNITY

Differential Gene Expression and Translational Approaches to Identify Biomarkers of Interferon Beta Activity in Multiple Sclerosis

(2010) Ed Croze   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

MxA: A biomarker for predicting multiple sclerosis disease activity

(2010) A. T. Reder   NEUROLOGY

Cross-sectional study assessing long-term safety of interferon- -1b for relapsing-remitting MS

(2010) A. T. Reder et al.   NEUROLOGY

Pathway Commons, a web resource for biological pathway data

(2010) E. G. Cerami et al.   NUCLEIC ACIDS RESEARCH

Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-β-1b treatment in relapsing remitting MS

(2010) Robert H Goertsches et al.   PHARMACOGENOMICS

IFN-β pharmacogenomics in multiple sclerosis

(2010) Koen Vandenbroeck et al.   PHARMACOGENOMICS

The challenge of multiple sclerosis: How do we cure a chronic heterogeneous disease?

(2009) Howard L. Weiner   ANNALS OF NEUROLOGY

Is multiple sclerosis a mitochondrial disease?

(2009) Peizhong Mao et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

A type I interferon signature in monocytes is associated with poor response to interferon-β in multiple sclerosis

(2009) M. Comabella et al.   BRAIN

The Protein Kinase IKKɛ Regulates Energy Balance in Obese Mice

(2009) Shian-Huey Chiang et al.   CELL

Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score

(2009) Philip L De Jager et al.   LANCET NEUROLOGY

Interferon-  mechanisms of action in multiple sclerosis

(2009) S. Dhib-Jalbut et al.   NEUROLOGY

OLA1, an Obg-like ATPase, suppresses antioxidant response via nontranscriptional mechanisms

(2009) J. Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Synergistic benefit in inflammatory arthritis by targeting I B kinase   and interferon  

(2008) M Corr et al.   ANNALS OF THE RHEUMATIC DISEASES

IFN-β1b Induces Transient and Variable Gene Expression in Relapsing-Remitting Multiple Sclerosis Patients Independent of Neutralizing Antibodies or Changes in IFN Receptor RNA Expression

(2008) Anthony T. Reder et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

IFN-β-regulated genes show abnormal expression in therapy-naïve relapsing–remitting MS mononuclear cells: Gene expression analysis employing all reported protein–protein interactions

(2008) Ken D. Yamaguchi et al.   JOURNAL OF NEUROIMMUNOLOGY

Neurodegeneration in multiple sclerosis: The role of oxidative stress and excitotoxicity

(2008) R.E. Gonsette   JOURNAL OF THE NEUROLOGICAL SCIENCES

Molecular mechanisms of Nrf2-mediated antioxidant response

(2008) Wenge Li et al.   MOLECULAR CARCINOGENESIS

Pharmacogenomics of IFN-β in multiple sclerosis: towards a personalized medicine approach

(2008) Saskia Vosslamber et al.   PHARMACOGENOMICS

Pharmacogenomics of Interferon-ß Therapy in Multiple Sclerosis: Baseline IFN Signature Determines Pharmacological Differences between Patients

(2008) Lisa G. M. van Baarsen et al.   PLoS One